Maricann Group (CNSX:MARI) Stock Price Expected to Rise, BMO Capital Markets Analyst Says

Maricann Group (CNSX:MARI) had its target price boosted by BMO Capital Markets from $7.00 to $9.50 in a research report released on Friday morning,BayStreet.CA reports. BMO Capital Markets currently has an outperform rating on the stock.

Maricann Group Price Performance

Maricann Group has a 12-month low of $0.87 and a 12-month high of $3.60.

Maricann Group Company Profile

Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.